Jenoptik AG (0ZPV)
London Exchange · UK · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 37.25 |
|---|---|
| 52-week range | 18.23 – 48.42 |
| Return, 1 month / 3 months | −11.1% / −4.9% |
| Return, 1 year / 3 years | +90.1% / +91.1% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 44 |
| Volatility (1 year) | 49.3% |
| Worst drawdown (1 year) | -26.2% |
| Average daily value traded | 1.11M EUR |
| Dividend yield | 1.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Jenoptik AG is a German photonics company based in Jena. It develops and supplies optical systems, laser processing machines and industrial metrology equipment, along with traffic monitoring and safety systems. Its customers come from the automotive, semiconductor, medical technology and defence industries, as well as public authorities that use its road traffic technology. The company combines optics, precision mechanics and electronics to serve industrial and institutional markets, and it operates manufacturing and sales sites in several countries.
Jenoptik AG trades under the code 0ZPV on the London Exchange in UK, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Jenoptik AG (0ZPV) trades on the London Exchange in UK. It last closed at EUR 37.25 on 23 October 2026.
Its price-based Market X-Ray is 55 out of 100 (a fair price profile), ranking 1,740 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 90.1% and over the last three months it fell 4.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 64 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 4.6% | ||
| From 52-week high | -22.5% | ||
| Momentum | 69 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -4.9% | ||
| 6-month return | 10.2% | ||
| 12-month return, skipping the last month | 113.7% | ||
| Stability (higher is calmer) | 43 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 49.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -26.2% | ||
| Liquidity | 54 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.11M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 29 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.1% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +1.0% |
|---|---|
| 1 month | −11.1% |
| 3 months | −4.9% |
| 6 months | +10.2% |
| 1 year | +90.1% |
| 3 years | +91.1% |
| 5 years | +23.1% |
Signals
| 50-day / 200-day average | 39.86 / 35.62 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.94 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 10 Jun 2026 | EUR 0.4000 |
| 13 Jun 2025 | EUR 0.3800 |
| 19 Jun 2024 | EUR 0.3500 |
| 8 Jun 2023 | EUR 0.3000 |
| 16 Jun 2022 | EUR 0.2500 |
| 10 Jun 2021 | EUR 0.2500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.